Listing of Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-54. (Previously Canceled Without Prejudice)
- 55. (Previously Amended) A method of treating sleep apnea or sleep induced apnea in a patient which comprises administering to a patient in need of said treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
 - 56. (Previously Canceled Without Prejudice).
- 57. (Original) The method of claim 55, wherein the patient is a human.
- 58. (Original) The method of claim 55, wherein (+) norcisapride is administered orally.
- 59. (Original) The method of claim 58, wherein (+) norcisapride is administered as a tablet or a capsule.
- 60. (Original) The method of claim 55, wherein the amount administered is from about 0.5 mg to about 500 mg.
- 61. (Original) The method of claim 60, wherein the amount administered is from about 1 mg to about 250 mg.
- 62. (Original) The method of claim 55, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.
- 63. (Original) The method of claim 58, wherein said (+) norcisapride is administered from one to four times per day.

2 DCJD: 500920.1

64. (Original) The method of claim 55, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

65-70. (Previously Canceled Without Prejudice)

- 71. (Currently Amended) A method of preventing or managing sleep apnea or sleep induced apnea in a patient which comprises administering to a patient in need of said prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
- 72. (Previously Added) The method of claim 71, wherein the patient is a human.
- 73. (Previously Added) The method of claim 71, wherein (+) norcisapride is administered orally.
- 74. (Previously Added) The method of claim 73, wherein (+) norcisapride is administered as a tablet or a capsule.
- 75. (Previously Added) The method of claim 71, wherein the amount administered is from about 0.5 mg to about 500 mg.
- 76. (Previously Added) The method of claim 75, wherein the amount administered is from about 1 mg to about 250 mg.
- 77. (Previously Added) The method of claim 71, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.
- 78. (Previously Added) The method of claim 73, wherein said (+) norcisapride is administered from one to four times per day.
- 79. (Previously Added) The method of claim 71, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

3 DCJD: 500920.1